Compare iShares MSCI Taiwan ETF (EWT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Mesoblast Limited — how do they compare? iShares MSCI Taiwan ETF trades at $106.45, while Mesoblast Limited trades at $16.8 (market cap $2.21B). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| EWT | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $111.53 | $20.96 |
52-Week Low | $58.05 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $106.34, up 4.07% with strong bullish momentum. Technical indicators show moving averages strongly bullish while oscillators are neutral. The ETF benefits from Taiwan's AI-driven semiconductor exposure, with TSMC representing 22.5% weighting. Recent news highlights Taiwan's strong 2026 performance driven by AI chip demand, though some rotation from Asian AI winners has occurred.
Outlook remains positive given Taiwan's critical semiconductor role and AI infrastructure demand. Key risks include geopolitical tensions with China, foreign capital outflows, and semiconductor cycle volatility. The ETF's heavy tech concentration provides growth potential but increases sector-specific risk exposure.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
